GROUP PERFORMANCE

  • arrow up

    Revenue
    increased by
    11%  to R21,9 billion

    Strong organic and acquisitive growth from Commercial Pharmaceuticals with the Thrombosis and Anaesthetics portfolios being the main contributors. Revenue increased by 11% on a constant exchange rate (“CER*”) basis.

  • arrow up

    Normalised EBITDA
    increased by
    15% to R6,3 billion

    Normalised EBITDA, comprising operating profit before depreciation and amortisation adjusted for specific non-trading items, grew 15% (up 13% on a CER* basis) led by growth in Therapeutic Focused Brands supported by consistent underlying performance from Regional Brands.

  • arrow up

    Earnings per share
    increased by
    30% to 806,0 cents

    Reflects organic and acquisitive growth (up 29% on a CER* basis) supported by an effective supply chain.


  • arrow up

    Headline earnings
    per share increased by
    31%  to 842,5 cents

    Reflects organic and acquisitive growth (up 31% on a CER* basis) supported by an effective supply chain.

  • arrow up

    Normalised headline earnings
    per share increased by
    26%  to 871,9 cents

    Normalised headline earnings per share (up 25% on a CER* basis) comprises headline earnings per share adjusted for specific non-trading items and is a measure which provides clear comparability of the financial performance of Aspen’s ongoing underlying business. Solid growth in normalised EBITDA coupled with lower net financing costs augmented the growth in normalised headline earnings.

  • Acquisition of the residual
    rights to the AZ Anaesthetics
    portfolio concluded

    The closing conditions for the acquisition of the residual rights to the AZ Anaesthetics portfolio were concluded and the transaction became effective from 1 October 2017. This has led to an expanded gross margin in Therapeutic Focused Brands and is expected to enhance Aspen’s ability to maximise the value of this portfolio through product development and market leverage opportunities.

* The constant exchange rate (“CER”) restatement has been calculated by adjusting the prior year’s reported results at the current year’s reported exchange rate. This provides illustrative comparability with the current year’s reported performance.




Revenue 2017: Commercial Pharmaceuticals by region
 
Revenue December 2017 by business segment
Revenue by business segment


Revenue December 2017







Normalised EBITDA December 2017







Normalised headline earnings per share